Advaxis, Inc. Advaxis Immunotherapies Complement PD-1 Antibodies - WOWK 13 Charleston, Huntington WV News, Weather, Sports

Advaxis, Inc. Advaxis Immunotherapies Complement PD-1 Antibodies

Posted: Updated:

Advaxis Inc.
(NASDAQ:ADXS) today published a new blog post on The Chairman’s
Blog, written by the company’s CSO, Dr. Robert Petit.
TheChairmansBlog.com is an exclusive online media publication that
provides key executive officers and key opinion leaders a unique
platform to share insights about company and industry trends.

Advaxis CSO, Dr. Robert Petit,
published a new blog post about his recent participation in the
Bloomberg 2014 State of Healthcare Summit and the future of
immunotherapies in cancer treatment. Dr. Petit blogs about “learning
that cancer is really an individual disease within each patient”
and the work Advaxis is doing with Dr. Khleif to develop an
immunotherapy platform that will be complementary to current
immunotherapies. Read the full blog post on TheChairmansBlog.com
(http://www.thechairmansblog.com/advaxis/robert-petit/advaxis-immunotherapies-complement-pd-1-antibodies/)

About Advaxis, Inc.

Advaxis is a clinical-stage
biotechnology company developing the next generation of cancer
immunotherapies. Advaxis immunotherapies are based on a novel
platform technology using live, attenuated bacteria that are
bio-engineered to secrete an antigen/adjuvant fusion protein(s) that
is designed to redirect the powerful immune response all human beings
have to the bacterium to the cancer itself.

ADXS-HPV is currently being evaluated
in Phase 1 and 2 clinical trials for HPV-associated cancers:
recurrent cervical cancer (completed Phase 2 study conducted in
India), locally advanced cervical cancer (GOG/NCI U.S. study,
Clinical Trials.gov Identifier NCT01266460), head & neck cancer
(CRUK study, Clinical Trials.gov Identifier NCT01598792, Mt. Sinai
study, Clinical Trials.gov Identifier NCT02002182), and anal cancer
(BrUOG U.S. study, Clinical Trials.gov Identifier NCT01671488).
Advaxis has over 15 distinct immunotherapies in various stages of
development, developed directly by Advaxis and through strategic
collaborations with recognized centers of excellence such as: the
University of Pennsylvania, the Georgia Regents University Cancer
Center, Icahn School of Medicine at Mount Sinai, and others.

For more information please visit:
www.advaxis.com

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive,
online media publication where publically and privatively held firms
alike share insights about their companies and industries.
TheChairmansBlog.com enables upper tier management to discuss issues
that are of importance to their stakeholders, shareholders, and
interested parties in an informal environment. In addition to
management`s insightful blog posts, TheChairmansBlog.com staff and
aggregate partners contribute articles on finance, technology,
health, and energy while providing updated market trends, news, and
information. http://www.thechairmansblog.com/

ReleaseID: 412046